AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
18 February 2023 - 12:55AM
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or
the “Company”), an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases — including COVID-19, the
disease caused by the SARS-CoV-2 virus — today announced it will
participate in an event hosted by Solve M.E. Diagnostics and The
Biotechnology Innovation Organization (BIO) titled, “Long Covid:
What Will It Take To Accelerate Therapeutic Progress?,” being held
virtually on Tuesday, February 21, 2023, from 10:00 AM – 1:00 PM
PT.
The goal of the virtual event is to convene
stakeholders to advance research and development to diagnose and
treat Long Covid, ME/CFS, and post-infection diseases. By
increasing awareness among drug developers to the unmet needs of
our communities, Solve M.E. hopes to inspire industry players to
study these diseases and create therapeutic breakthroughs. The
session will also feature solution-oriented perspectives from
government, academic, and industry researchers; patient groups;
funding sources; and policymakers.
As part of the event, Thomas K. Equels, M.S.,
J.D., Chief Executive Officer of AIM ImmunoTech, will discuss the
clinical development plans for Ampligen (rintatolimod) for the
treatment of ME/CFS and Long COVID. Ampligen is AIM’s dsRNA product
candidate being developed for globally important cancers, viral
diseases and disorders of the immune system. The Company is
currently sponsoring an ongoing, FDA-authorized AMP-511
(ClinicalTrials.gov: NCT00215813) Expanded Access Program for
ME/CFS patients in the United States, which has been amended to
include Long COVID patients. Preliminary results based on data from
the first 4 Long COVID patients, following at least 12 weeks of
Ampligen treatment, indicated they had experienced a reduction in
fatigue, as measured via Patient-Reported Outcomes questionnaires.
A statistical analysis of these data indicated that the decrease in
fatigue compared to baseline was statistically significant
(p=0.002), despite the small number of patients. Based in part on
these early positive data, the FDA provided clearance of the
Company’s IND application for a Phase 2 study of Ampligen for the
treatment of Post-COVID Conditions (AMP-518) (ClinicalTrials.gov:
NCT05592418). The Company expects to commence patient enrollment in
AMP-518 in Q1 2023.
To register for the event, please click
here.
About Solve M.E.
The Solve ME/CFS Initiative (Solve M.E.) is a
non-profit organization that serves as a catalyst for critical
research into diagnostics, treatments, and cures for myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid and
other post-infection diseases.
Solve M.E.’s. work with the scientific, medical,
and pharmaceutical communities, advocacy with government agencies,
and alliances with patient groups around the world is laying the
foundation for breakthroughs that can improve the lives of millions
who suffer from various “long haul” diseases.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19. The Company’s lead product, Ampligen®
(rintatolimod) is an immuno-modulator with broad spectrum activity
being developed for globally important cancers, viral diseases and
disorders of the immune system.
Ampligen is currently being used to treat
pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at
Erasmus Medical Center and AIM has commenced a Phase 2 clinical
study in locally advanced pancreatic cancer. The Company also has
multiple ongoing clinical trials to evaluate Ampligen as a
combinational therapy for the treatment of a variety of solid tumor
types both underway and planned at major cancer research centers.
Additionally, Ampligen is approved in Argentina for the treatment
of severe chronic fatigue syndrome (CFS) and is currently being
evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID
Conditions.
For more information, please visit aimimmuno.com
and connect with the Company on Twitter, LinkedIn, and
Facebook.
Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. The results discussed above are subject to a
number of unknowns including, but not limited to, that while the
preliminary data in a small number of subjects shows significance,
no assurance can be given that these findings will prove true or
that the study will yield favorable results, and that significant
additional testing and trials will be required to determine whether
Ampligen will be an effective treatment for Long Covid. Among other
things, for those statements, the Company claims the protection of
safe harbor for forward-looking statements contained in the PSLRA.
The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024